Targeting proteins with metal complexes.
暂无分享,去创建一个
[1] S. Knapp,et al. Extremely Tight Binding of a Ruthenium Complex to Glycogen Synthase Kinase 3 , 2008, Chembiochem : a European journal of chemical biology.
[2] Ronen Marmorstein,et al. Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. , 2008, Journal of the American Chemical Society.
[3] H. Gray,et al. Enantiomer-specific binding of ruthenium(II) molecular wires by the amine oxidase of Arthrobacter globiformis. , 2008, Journal of the American Chemical Society.
[4] R. Webster,et al. Similar biological activities of two isostructural ruthenium and osmium complexes. , 2008, Chemistry.
[5] M. Herlyn,et al. Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. , 2008, ACS chemical biology.
[6] D. Rehder. The trigonal-bipyramidal NO4 ligand set in biologically relevant vanadium compounds and their inorganic models. , 2008, Journal of inorganic biochemistry.
[7] J. Suh,et al. Metal complexes as artificial proteases: toward catalytic drugs. , 2008, Current opinion in chemical biology.
[8] Seann P. Mulcahy,et al. Solid-phase synthesis of tris-heteroleptic ruthenium(II) complexes and application to acetylcholinesterase inhibition. , 2008, Inorganic chemistry.
[9] J. Cowan,et al. Catalytic inactivation of human carbonic anhydrase I by a metallopeptide-sulfonamide conjugate is mediated by oxidation of active site residues. , 2008, Journal of the American Chemical Society.
[10] H. Gray,et al. Probing inducible nitric oxide synthase with a pterin-ruthenium(II) sensitizer wire. , 2008, Angewandte Chemie.
[11] T. Kodadek,et al. A general system for evaluating the efficiency of chromophore-assisted light inactivation (CALI) of proteins reveals Ru(II) tris-bipyridyl as an unusually efficient "warhead". , 2008, Molecular bioSystems.
[12] S. Fricker. Metal based drugs: from serendipity to design. , 2007, Dalton transactions.
[13] T. Hambley. Developing new metal-based therapeutics: challenges and opportunities. , 2007, Dalton transactions.
[14] Junghun Suh,et al. Cleavage Agents for Soluble Oligomers of Amyloid β Peptides , 2007 .
[15] P. Sadler,et al. Using coordination chemistry to design new medicines , 2007 .
[16] Eric Meggers,et al. Exploring biologically relevant chemical space with metal complexes. , 2007, Current opinion in chemical biology.
[17] R. Webster,et al. Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand. , 2007, Organic & biomolecular chemistry.
[18] Seann P. Mulcahy,et al. Exploring Chemical Space with Organometallics: Ruthenium Complexes as Protein Kinase Inhibitors , 2007 .
[19] Eric Meggers,et al. Platinum complex as a nanomolar protein kinase inhibitor. , 2007, Inorganic chemistry.
[20] B. Brooks,et al. Engineering Metal Complexes of Chiral Pentaazacrowns as Privileged Reverse‐turn Scaffolds , 2007, Chemical biology & drug design.
[21] Simon Parsons,et al. Configurations of nickel-cyclam antiviral complexes and protein recognition. , 2007, Chemistry.
[22] K. Flaherty,et al. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. , 2007, Cancer research.
[23] E. Lam,et al. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). , 2006, ACS chemical biology.
[24] H. Bregman,et al. Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety. , 2006, Organic letters.
[25] G. E. Atilla‐Gokcumen,et al. Organometallic Compounds with Biological Activity: A Very Selective and Highly Potent Cellular Inhibitor for Glycogen Synthase Kinase 3 , 2006, Chembiochem : a European journal of chemical biology.
[26] J. Cowan,et al. Metallopeptide-promoted inactivation of angiotensin-converting enzyme and endothelin-converting enzyme 1: toward dual-action therapeutics , 2006, JBIC Journal of Biological Inorganic Chemistry.
[27] S. Fricker,et al. Rhenium inhibitors of cathepsin B (ReO(SYS)X (where Y = S, py; X = Cl, Br, SPhOMe-p)): Synthesis and mechanism of inhibition. , 2006, Journal of medicinal chemistry.
[28] N. Farrell,et al. Targeting retroviral Zn finger-DNA interactions: a small-molecule approach using the electrophilic nature of trans-platinum-nucleobase compounds. , 2006, Chemistry & biology.
[29] Garland R. Marshall,et al. Development of small molecules designed to modulate protein–protein interactions , 2006, J. Comput. Aided Mol. Des..
[30] P. Dyson,et al. Metal-based antitumour drugs in the post genomic era. , 2006, Dalton transactions.
[31] C. Che,et al. A mixed-valent ruthenium-oxo oxalato cluster Na7[Ru4(mu3-O)4(C2O4)6] with potent anti-HIV activities. , 2006, Journal of the American Chemical Society.
[32] K. Fritz-Wolf,et al. Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. , 2006, Angewandte Chemie.
[33] D. Christianson,et al. Ultrahigh resolution crystal structures of human carbonic anhydrases I and II complexed with "two-prong" inhibitors reveal the molecular basis of high affinity. , 2006, Journal of the American Chemical Society.
[34] S. Knapp,et al. Ruthenium half-sandwich complexes bound to protein kinase Pim-1. , 2006, Angewandte Chemie.
[35] N. Metzler‐Nolte,et al. New principles in medicinal organometallic chemistry. , 2006, Angewandte Chemie.
[36] Eric Meggers,et al. Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. , 2006, Journal of the American Chemical Society.
[37] J. Cowan,et al. Inactivation of human angiotensin converting enzyme by copper peptide complexes containing ATCUN motifs. , 2005, Chemical communications.
[38] H. Gray,et al. Picosecond photoreduction of inducible nitric oxide synthase by rhenium(I)-diimine wires. , 2005, Journal of the American Chemical Society.
[39] H. Gray,et al. Reversible inhibition of copper amine oxidase activity by channel-blocking ruthenium(II) and rhenium(I) molecular wires. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] Melissa L. Golden,et al. Thiolate-bridged heterodinuclear platinum-zinc chelates as models for ternary platinum-DNA-protein complexes and zinc ejection from zinc fingers. Evidence from studies using ESI-mass spectrometry. , 2005, Chemical communications.
[41] S. Mallik,et al. Inhibition of matrix metalloproteinase-9 by "multi-prong" surface binding groups. , 2005, Chemical communications.
[42] J. Suh,et al. Angiotensin-cleaving catalysts: conversion of N-terminal aspartate to pyruvate through oxidative decarboxylation catalyzed by Co(III)cyclen , 2005, JBIC Journal of Biological Inorganic Chemistry.
[43] Douglas S. Williams,et al. Switching on a signaling pathway with an organoruthenium complex. , 2005, Angewandte Chemie.
[44] A. Vessières,et al. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior. , 2005, Journal of medicinal chemistry.
[45] Simon Parsons,et al. Protein recognition of macrocycles: binding of anti-HIV metallocyclams to lysozyme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[46] Hwangseo Park,et al. Peptide-cleaving catalyst selective for peptide deformylase. , 2005, Journal of the American Chemical Society.
[47] R. Gust,et al. Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action. , 2005, Journal of medicinal chemistry.
[48] A. Vessières,et al. Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates. , 2005, Angewandte Chemie.
[49] H. Sekizaki,et al. Amidino-containing Schiff base copper(II) and iron(III) chelates as a thrombin inhibitor. , 2005, Chemical & pharmaceutical bulletin.
[50] W. Hol,et al. The power of vanadate in crystallographic investigations of phosphoryl transfer enzymes , 2004, FEBS letters.
[51] Douglas S. Williams,et al. An organometallic inhibitor for glycogen synthase kinase 3. , 2004, Journal of the American Chemical Society.
[52] G. Leclercq,et al. The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer. , 2004, Current medicinal chemistry.
[53] Michael S. Cohen,et al. Electron-transfer chemistry of Ru-linker-(heme)-modified myoglobin: rapid intraprotein reduction of a photogenerated porphyrin cation radical. , 2004, Inorganic chemistry.
[54] E. Meggers,et al. Ruthenium complexes as protein kinase inhibitors. , 2004, Organic letters.
[55] P. Sadler,et al. Anti-viral cyclam macrocycles : rapid zinc uptake at physiological pH. , 2004, Chemical communications.
[56] H. Sakurai,et al. Synthesis and insulinomimetic activities of novel mono- and tetranuclear oxovanadium(IV) complexes with 3-hydroxypyridine-2-carboxylic acid. , 2004, Journal of inorganic biochemistry.
[57] T. Kodadek,et al. Using oxidative crosslinking and proximity labeling to quantitatively characterize protein-protein and protein-Peptide complexes. , 2003, Chemistry & biology.
[58] P. Sadler,et al. Selective recognition of configurational substates of zinc cyclam by carboxylates: implications for the design and mechanism of action of anti-HIV agents. , 2003, Chemistry.
[59] H. Gray,et al. Nanosecond photoreduction of cytochrome p450cam by channel-specific Ru-diimine electron tunneling wires. , 2003, Journal of the American Chemical Society.
[60] Nohad Gresh,et al. Modeling of Copper(II) Complexes with the SIBFA Polarizable Molecular Mechanics Procedure. Application to a New Class of HIV-1 Protease Inhibitors , 2003 .
[61] C. Orvig,et al. Boon and Bane of Metal Ions in Medicine , 2003, Science.
[62] Kasper P. Jensen,et al. Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. , 2003, Biochemistry.
[63] Zoran Radić,et al. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site , 2003, The EMBO journal.
[64] S. Son,et al. Protein-cleaving catalyst selective for protein substrate. , 2002, Organic letters.
[65] Chris M. W. Ho,et al. Metal complexes of chiral pentaazacrowns as conformational templates for β-turn recognition , 2002, J. Comput. Aided Mol. Des..
[66] Xiangyang Liang,et al. Structure and dynamics of metallomacrocycles: recognition of zinc xylyl-bicyclam by an HIV coreceptor. , 2002, Journal of the American Chemical Society.
[67] A. Mouithys-Mickalad,et al. Metal-organic compounds: a new approach for drug discovery. N1-(4-methyl-2-pyridyl)-2,3,6-trimethoxybenzamide copper(II) complex as an inhibitor of human immunodeficiency virus 1 protease. , 2002, Biochemical pharmacology.
[68] H. Gray,et al. Sensitizer-linked substrates and ligands: ruthenium probes of cytochrome P450 structure and mechanism. , 2002, Methods in enzymology.
[69] A. Dunn,et al. Probing the open state of cytochrome P450cam with ruthenium-linker substrates , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[70] B C Roy,et al. Surface recognition of a protein using designed transition metal complexes. , 2001, Journal of the American Chemical Society.
[71] A. Tracey,et al. Vanadium(V) complexes in enzyme systems: aqueous chemistry, inhibition and molecular modeling in inhibitor design. , 2001, Journal of inorganic biochemistry.
[72] M. James,et al. X-ray crystallographic analyses of complexes between bovine beta-trypsin and Schiff base copper(II) or iron(III) chelates. , 2001, Journal of molecular biology.
[73] T. Kodadek,et al. Scope, limitations and mechanistic aspects of the photo-induced cross-linking of proteins by water-soluble metal complexes. , 2000, Chemistry & biology.
[74] Zou,et al. First Crystal Structure of a Medicinally Relevant Gold Protein Complex: Unexpected Binding of , 2000, Angewandte Chemie.
[75] H. Gray,et al. Optical detection of cytochrome P450 by sensitizer-linked substrates. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[76] Tomohiko Maehama,et al. Crystal Structure of the PTEN Tumor Suppressor Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association , 1999, Cell.
[77] C. Shaw. Gold-Based Therapeutic Agents , 1999 .
[78] T. Meade,et al. Metal complexes as enzyme inhibitors. , 1999, Chemical reviews.
[79] D. Riley. Functional mimics of superoxide dismutase enzymes as therapeutic agents. , 1999, Chemical reviews.
[80] P. Sadler,et al. Metals in Medicine. , 1999, Angewandte Chemie.
[81] T. Kodadek,et al. Chemistry for the analysis of protein-protein interactions: rapid and efficient cross-linking triggered by long wavelength light. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[82] H. Gray,et al. Substrates for Rapid Delivery of Electrons and Holes to Buried Active Sites in Proteins , 1999 .
[83] F. Durant,et al. De novo drug design of a new copper chelate molecule acting as HIV-1 protease inhibitor , 1998 .
[84] M. Simon,et al. Selective Inhibition of Human α-Thrombin by Cobalt(III) Schiff Base Complexes , 1998 .
[85] T. Meade,et al. A cobalt complex that selectively disrupts the structure and function of zinc fingers. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[86] R. Schinazi,et al. Polyoxometalates in Medicine. , 1998, Chemical reviews.
[87] A. Walts,et al. Protease activity of 1,10-phenanthroline-copper(I). Targeted scission of the catalytic site of carbonic anhydrase. , 1998, Biochemistry.
[88] M. Gresser,et al. Mechanism of Inhibition of Protein-tyrosine Phosphatases by Vanadate and Pervanadate* , 1997, The Journal of Biological Chemistry.
[89] M. Zhou,et al. Crystal structure of bovine low molecular weight phosphotyrosyl phosphatase complexed with the transition state analog vanadate. , 1997, Biochemistry.
[90] D G Jay,et al. Chromophore-assisted laser inactivation (CALI): probing protein function in situ with a high degree of spatial and temporal resolution. , 1996, Trends in cell biology.
[91] H. Matter,et al. Structures, Dynamics, and Biological Activities of 15 Cyclic Hexapeptide Analogs of the .alpha.-Amylase Inhibitor Tendamistat (HOE 467) in Solution , 1995 .
[92] M. Lipton,et al. Cyclic hexapeptides and chimeric peptides as mimics of tendamistat , 1994 .
[93] Peter G. Schultz,et al. A new strategy for selective protein cleavage , 1990 .
[94] Alanna Schepartz,et al. Site-Specific Cleavage of the Protein Calmodulin Using a Trifluoperazine-Based Affinity Reagent , 1990 .
[95] F. P. Dwyer,et al. The biological actions of 1,10-phenanthroline and 2,2'-bipyridine hydrochlorides, quaternary salts and metal chelates and related compounds. 1. Bacteriostatic action on selected gram-positive, gram-negative and acid-fast bacteria. , 1969, The Australian journal of experimental biology and medical science.
[96] E. Mayhew,et al. Inhibition of Landschütz Ascites Tumour Growth by Metal Chelates Derived from 3,4,7,8-Tetramethyl-1,10-phenanthroline , 1965, British Journal of Cancer.
[97] F. P. Dwyer,et al. Effect of Inorganic Complex Ions on Transmission at a Neuromuscular Junction , 1957, Nature.
[98] F. P. Dwyer,et al. The Metabolic Fate of Tris-1,10-Phenanthroline 106Ruthenium (II) Perchlorate, a Compound With Anticholinesterase and Curare-Like Activity , 1957 .
[99] F. P. Dwyer,et al. Biological Activity of Complex Ions , 1952, Nature.